biotech
FDA Approves Novartis' Hypertension Drug Tekturna
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on March 8, 2007
FDA Approves Novartis' Hypertension Drug Tekturna
The US FDA has approved Novartis' new hypertension drug, Tekturna (aliskiren), a direct renin inhibitor. A once-daily oral tablet therapy, Tekturna acts by blocking renin, an enzyme responsible for triggering a process that can contribute to high blood pressure.
"Renin angiotensin system activity contributes to many of the complications associated with high blood pressure," said Marc A. Pfeffer, MD, PhD, Professor of Medicine at the Harvard Medical School and cardiologist at Brigham & Women's Hospital. "By inhibiting this important system at its origin, renin production, a direct renin inhibitor such as Tekturna offers an exciting novel therapeutic option for treating hypertension."

The drug has been approved as monotherapy, as well as in combination with other medications to control blood blood pressure. It is expected to be available in the pharmacies within the month.

For more info, see Novartis press release or the financial report from CNN Money.


Permalink: FDA Approves Novartis' Hypertension Drug Tekturna
Tags: hypertension  Tekturna  blood+pressure  cardiovascular+disease  heart+health  health  biotech  hypertension 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/57100
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for FDA Approves Novartis' Hypertension Drug Tekturna:

  • Currently 9.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.00 out of 5 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!